PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.22%
Positive revenue growth while 3141.T is negative. John Neff might see a notable competitive edge here.
0.43%
Positive gross profit growth while 3141.T is negative. John Neff would see a clear operational edge over the competitor.
3.96%
Positive EBIT growth while 3141.T is negative. John Neff might see a substantial edge in operational management.
4.58%
Positive operating income growth while 3141.T is negative. John Neff might view this as a competitive edge in operations.
3.45%
Positive net income growth while 3141.T is negative. John Neff might see a big relative performance advantage.
3.44%
Positive EPS growth while 3141.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
3.44%
Positive diluted EPS growth while 3141.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while 3141.T is at 0.11%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3141.T is at 0.28%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
4.61%
OCF growth above 1.5x 3141.T's 2.00%. David Dodd would confirm a clear edge in underlying cash generation.
4.61%
FCF growth above 1.5x 3141.T's 2.00%. David Dodd would verify if the firm’s strategic investments yield superior returns.
24.33%
10Y revenue/share CAGR under 50% of 3141.T's 156.44%. Michael Burry would suspect a lasting competitive disadvantage.
44.56%
5Y revenue/share CAGR at 50-75% of 3141.T's 61.99%. Martin Whitman would worry about a lagging mid-term growth trajectory.
20.69%
3Y revenue/share CAGR at 50-75% of 3141.T's 32.34%. Martin Whitman would question if the firm lags behind competitor innovations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.06%
Below 50% of 3141.T's 63.17%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
21.77%
5Y net income/share CAGR 1.25-1.5x 3141.T's 18.02%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
-8.85%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
138.51%
10Y equity/share CAGR at 50-75% of 3141.T's 262.44%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
97.30%
5Y equity/share CAGR 1.25-1.5x 3141.T's 73.47%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
46.99%
3Y equity/share CAGR 1.25-1.5x 3141.T's 41.09%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
88.89%
Dividend/share CAGR of 88.89% while 3141.T is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
No Data
No Data available this quarter, please select a different quarter.
-2.02%
Firm’s AR is declining while 3141.T shows 1.32%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-1.88%
Inventory is declining while 3141.T stands at 8.62%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.52%
Negative asset growth while 3141.T invests at 0.54%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.65%
BV/share growth above 1.5x 3141.T's 0.52%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
73.31%
We have some new debt while 3141.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
We cut SG&A while 3141.T invests at 1.63%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.